Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
Lopez Guerra JL, Gladish G, Komaki R, Gomez D, Zhuang Y, Liao Z.
J Nucl Med. 2012 Feb;53(2):225-33. Epub 2012 Jan 12.
Related citations
Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D, Mundigl O, Wessner A, Gremse F, Bachmann J, Rodriguez A, Klingmüller U, Jarsch M, Kiessling F, Lederle W.
J Nucl Med. 2012 Feb;53(2):304-11. Epub 2012 Jan 6.
4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
Minamimoto R, Toyohara J, Seike A, Ito H, Endo H, Morooka M, Nakajima K, Mitsumoto T, Ito K, Okasaki M, Ishiwata K, Kubota K.
J Nucl Med. 2012 Feb;53(2):199-206. Epub 2011 Dec 21.
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C.
J Nucl Med. 2011 Dec;52(12):1871-7. Epub 2011 Nov 7.
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ.
J Nucl Med. 2011 Nov;52(11):1803-10.
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS.
J Nucl Med. 2011 Nov;52(11):1684-9.
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.
Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D.
J Nucl Med. 2011 Nov;52(11):1690-7. Epub 2011 Oct 11.
Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.
Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, Hoekstra OS, Lammertsma AA, Boellaard R.
J Nucl Med. 2011 Oct;52(10):1550-8. Epub 2011 Aug 17.
Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Herbrik M, Treffert J, Geiger B, Riegger C, Hartung V, Rosenbaum-Krumme SJ, Forsting M, Antoch G, Heusner TA.
J Nucl Med. 2011 Oct;52(10):1520-5. Epub 2011 Sep 9.
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Meng X, Loo BW Jr, Ma L, Murphy JD, Sun X, Yu J.
J Nucl Med. 2011 Oct;52(10):1573-9. Epub 2011 Sep 8.
Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
Brockenbrough JS, Souquet T, Morihara JK, Stern JE, Hawes SE, Rasey JS, Leblond A, Wiens LW, Feng Q, Grierson J, Vesselle H.
J Nucl Med. 2011 Aug;52(8):1181-8. Epub 2011 Jul 15.
Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.
Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N.
J Nucl Med. 2011 May;52(5):705-11. Epub 2011 Apr 15.
Impact of time-of-flight PET on whole-body oncologic studies: a human observer lesion detection and localization study.
Surti S, Scheuermann J, El Fakhri G, Daube-Witherspoon ME, Lim R, Abi-Hatem N, Moussallem E, Benard F, Mankoff D, Karp JS.
J Nucl Med. 2011 May;52(5):712-9. Epub 2011 Apr 15.
Autocontouring versus manual contouring.
Hatt M, Visvikis D, Le Rest CC.
J Nucl Med. 2011 Apr;52(4):658; author reply 658-9. Epub 2011 Mar 18. No abstract available.
Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I.
Wang F, Fang W, Zhang MR, Zhao M, Liu B, Wang Z, Hua Z, Yang M, Kumata K, Hatori A, Yamasaki T, Yanamoto K, Suzuki K.
J Nucl Med. 2011 Apr;52(4):592-9. Epub 2011 Mar 18.
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS.
J Nucl Med. 2011 Jan;52(1):48-55. Epub 2010 Dec 13.
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R.
J Nucl Med. 2010 Dec;51(12):1870-7. Epub 2010 Nov 15.
18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H.
J Nucl Med. 2010 Dec;51(12):1833-40. Epub 2010 Nov 15. Erratum in: J Nucl Med. 2011 Jan;52(1):106.
Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J, Weller J, Stargardt T, Herrmann K, Bluemel C, Dechow T, Glatting G, Krause BJ, Mottaghy F, Reske SN, Buck AK.
J Nucl Med. 2010 Nov;51(11):1668-75.
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer.
van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, Lammertsma AA, Lubberink M.
J Nucl Med. 2010 Nov;51(11):1684-90. Epub 2010 Oct 18.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on